Shire plc announced that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million. With the acquisition,...
On May 27, 2014, the European Medicines Agency (EMA) accepted Sanofi�s marketing authorization dossier for insulin glargine (rDNA origin) injection...
Romark announced initial results of a Phase III clinical trial of its investigational new drug candidate NT 300 (nitazoxanide extended-release tablets, 300 mg) versus placebo as a treatment for mild or moderate COVID-19 .
Baxter International Inc., a global leader in Parenteral Nutrition therapy, announced the European launch of Numeta G13E 300 ml, the...